Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

X-ray Imaging

X-ray Imaging

German physicist Wilhelm Röntgen (1845–1923) was experimenting with electrical current when he discovered that a mysterious and invisible "ray" would pass through his flesh but leave an outline of his bones on a screen coated with a metal compound. In 1895, Röntgen made the first durable record of the internal parts of a living human: an "X-ray" image (as it came to be called) of his wife’s hand. Scientists worldwide quickly began their own experiments with...

Imaging Studies IV: Magnetic Resonance Imaging

Imaging Studies IV: Magnetic Resonance Imaging

Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Incidental Finding of Gastric Adenocarcinoma on F-18 FES PET/CT in a Patient With Breast Cancer.

Clinical nuclear medicine·2026

Same author

Brain and Spinal Leptomeningeal Metastases in Prostate Cancer Detected by PSMA PET and MRI Fusion.

Clinical nuclear medicine·2026

Same author

Differentiated thyroid cancer and positron emission computed tomography: when, how and why?

Expert review of anticancer therapy·2025

Same author

The State-of-the-Art PET Tracers in Glioblastoma and High-grade Gliomas and Implications for Theranostics.

PET clinics·2024

Same author

F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury.

The Journal of clinical investigation·2024

Same author

Concomitant Pancreatitis and Pancreatic Neuroendocrine Tumor on MRI and 68 Ga-DOTATATE PET/CT.

Clinical nuclear medicine·2024

Same journal

Extremely Rare Primary Gastric Alveolar Rhabdomyosarcoma in an Adult: <sup>18</sup>F-FDG PET/CT Findings.

Molecular imaging and radionuclide therapy·2026

Same journal

An Exceptional Presentation of Hutch Diverticulum on Bone Scintigraphy.

Molecular imaging and radionuclide therapy·2026

Same journal

Pearls and Pitfalls of <sup>18</sup>F-FDG PET/CT for Suspected Alzheimer's Disease in Patient with Down Syndrome.

Molecular imaging and radionuclide therapy·2026

Same journal

<sup>68</sup>Ga-FAPI Avidity in Fat Necrosis and Adrenal Adenoma: Expanding the Spectrum of Benign Pitfalls in Oncologic Imaging.

Molecular imaging and radionuclide therapy·2026

Same journal

Follicular Thyroid Carcinoma with Cavernous Sinus Metastasis and Perineural Spread: A Rare Manifestation of Radioiodine-refractory Disease.

Molecular imaging and radionuclide therapy·2026

Same journal

Diffuse Gastric Uptake and Metabolic Superscan in the Patient with Multiple Myeloma.

Molecular imaging and radionuclide therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 8, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

I-124 Imaging and Dosimetry.

Russ Kuker¹, Manuel Sztejnberg, Seza Gulec

¹University of Miami Miller School of Medicine, Department of Radiology, Miami, USA, Phone: (305) 585-7955,

Molecular Imaging and Radionuclide Therapy

|January 25, 2017

Summary

This summary is machine-generated.

Iodine-124 (I-124) positron emission tomography (PET) offers improved imaging for differentiated thyroid cancer over standard methods. Further research is needed to optimize I-124 dosimetry for personalized treatment and minimize normal organ toxicity.

More Related Videos

Dosimetry for Cell Irradiation using Orthovoltage 40-300 kV X-Ray Facilities

Dosimetry for Cell Irradiation using Orthovoltage 40-300 kV X-Ray Facilities

Published on: February 20, 2021

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Related Experiment Videos

Last Updated: Mar 8, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Dosimetry for Cell Irradiation using Orthovoltage 40-300 kV X-Ray Facilities

Dosimetry for Cell Irradiation using Orthovoltage 40-300 kV X-Ray Facilities

Published on: February 20, 2021

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Area of Science:

Nuclear Medicine
Oncology
Radiochemistry

Background:

Radioactive iodine is a foundational theranostic agent in differentiated thyroid cancer (DTC) management.
Existing diagnostic techniques and dosimetry protocols require optimization for improved clinical outcomes.
Iodine-124 (I-124) presents an opportunity to enhance current theranostic approaches in DTC.

Purpose of the Study:

To explore the potential of I-124 positron emission tomography (PET) in improving the diagnosis and treatment of differentiated thyroid cancer.
To address the challenges and opportunities associated with I-124 quantitative imaging and dosimetry.
To discuss future directions for patient-specific treatment planning using I-124.

Main Methods:

Utilizing I-124 as a PET radiotracer for enhanced imaging of thyroid cancer.
Comparing PET/computed tomography (CT) with standard gamma scintigraphy for disease detection and volume assessment.
Reviewing historical perspectives and future concepts in I-124 imaging and dosimetry.

Main Results:

PET/CT offers superior sensitivity and spatial resolution for detecting recurrent or metastatic DTC compared to gamma scintigraphy.
I-124 PET enables more accurate measurement of metabolic tumor volumes.
The complex decay of I-124 presents challenges for quantitative PET imaging and dosimetry.

Conclusions:

I-124 PET holds significant promise for advancing the theranostics of differentiated thyroid cancer.
Prospective studies are essential to establish optimal dosimetry protocols for I-124.
Future strategies must balance tumor absorbed dose with normal organ toxicity for effective patient-specific treatment.